The Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons with REM Sleep Behavior Disorder (RBD)
Objective: To explore the potential for an immunologically based intervention to slow evolution of symptoms in persons with prodromal or Stage 2b (Simuni et al.…Choreiform Movements Secondary to Sarcoidosis Without Central Nervous System Granulomatosis
Objective: To share our experience managing a patient who presented with choreiform movements found to be secondary to sarcoidosis without CNS Granulomatosis. Background: Sarcoidosis is…The challenge to prevent Parkinson’s Disease with a new in vitro approach
Objective: This research line aims to perform a compound screening on the prophylactic capacity of a high number of nutraceuticals and drugs to prevent dopaminergic…A Survey of Immunological Mechanisms in Cervical Dystonia
Objective: The overall goal was to delineate which aspects of the immune system may be most relevant to the biology of CD. Background: Although several…Pharmacokinetics And Safety Of YA-101, A Dual Inhibitors Of D-Amino Acid Oxidase (DAAO) And NLRP3 Inflammasome, In Healthy Subjects: A Double-Blind, Placebo-Controlled, Randomized, Single Dose and Multiple Dose Phase I Study
Objective: To evaluate the safety, tolerability, and pharmacokinetics (PK) profile of YA-101 in healthy volunteers with single dose and multiple dose Background: Multiple System Atrophy…Targeting miR-27 with Antisense Oligonucleotides for Disease Modification in Parkinson’s Disease
Objective: Achieve disease modification in idiopathic Parkinson’s Disease through miR-27 targeting using Antisense Oligonucleotides Background: There are currently no disease-modifying therapies for Parkinson’s Disease (PD).…Investigating the genetic relationship between vitamin B12 deficiency and Parkinson’s disease
Objective: The aim of this study was to investigate the genetic association and causal link between vitamin B12 and the risk and progression of Parkinson's…Peripheral immune profile and neutrophil-to-lymphocyte ratio in Progressive Supranuclear Palsy
Objective: This study aimed to evaluate the peripheral immune profile in patients with Progressive Supranuclear Palsy (PSP) compared with patients with Parkinson’s disease (PD) and…Validating the clinical stage NLRP3 inflammasome inhibitor nibrozetone as a disease-modifying therapeutic for Parkinson’s disease
Objective: We recently confirmed that nibrozetone (RRx-001), a Phase 3 small molecule chemoprotective agent, is a direct NLRP3 inhibitor that is CNS permeable. Nibrozetone displays…Transcriptome analysis of proteasome and inflammation in the substantia nigra of Parkinson’s disease patients: the GEO database.
Objective: In this study, we analyzed transcriptome data regarding protein degradation pathways and inflammation sourced from GEO database. Background: Parkinson's disease (PD) is the second…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 22
- Next Page »